JP2003509494A5 - - Google Patents

Download PDF

Info

Publication number
JP2003509494A5
JP2003509494A5 JP2001524970A JP2001524970A JP2003509494A5 JP 2003509494 A5 JP2003509494 A5 JP 2003509494A5 JP 2001524970 A JP2001524970 A JP 2001524970A JP 2001524970 A JP2001524970 A JP 2001524970A JP 2003509494 A5 JP2003509494 A5 JP 2003509494A5
Authority
JP
Japan
Prior art keywords
compound
composition
combination
group
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001524970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/018358 external-priority patent/WO2001021590A1/en
Publication of JP2003509494A publication Critical patent/JP2003509494A/ja
Publication of JP2003509494A5 publication Critical patent/JP2003509494A5/ja
Pending legal-status Critical Current

Links

JP2001524970A 1999-09-22 2000-07-05 ムスカリン拮抗薬 Pending JP2003509494A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22
US09/401,391 1999-09-22
PCT/US2000/018358 WO2001021590A1 (en) 1999-09-22 2000-07-05 Muscarinic antagonists

Publications (2)

Publication Number Publication Date
JP2003509494A JP2003509494A (ja) 2003-03-11
JP2003509494A5 true JP2003509494A5 (enExample) 2007-08-16

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001524970A Pending JP2003509494A (ja) 1999-09-22 2000-07-05 ムスカリン拮抗薬

Country Status (14)

Country Link
EP (1) EP1214299B1 (enExample)
JP (1) JP2003509494A (enExample)
CN (1) CN1167682C (enExample)
AR (1) AR025459A1 (enExample)
AT (1) ATE264301T1 (enExample)
AU (1) AU5786300A (enExample)
CA (1) CA2384018C (enExample)
CO (1) CO5180624A1 (enExample)
DE (1) DE60009931T2 (enExample)
ES (1) ES2215055T3 (enExample)
HK (1) HK1043590A1 (enExample)
MX (1) MXPA02003136A (enExample)
PE (1) PE20010649A1 (enExample)
WO (1) WO2001021590A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2269774T3 (es) * 2001-10-10 2007-04-01 Schering Corporation Compuestos de piperidina como antagonistas muscarinicos.
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
TN2018000130A1 (en) 2015-11-06 2019-10-04 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2021113478A1 (en) 2019-12-06 2021-06-10 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2221399T3 (es) * 1998-06-30 2004-12-16 Schering Corporation Antagonistas muscarinicos.
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists

Similar Documents

Publication Publication Date Title
JP2001526218A5 (enExample)
JP2006507220A5 (enExample)
JP2005511592A5 (enExample)
JP2002541233A5 (enExample)
JP2003509349A5 (enExample)
JP2002502874A5 (enExample)
RU2002107975A (ru) Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения
JP2004531544A5 (enExample)
JP2002518502A5 (enExample)
RU2000132188A (ru) Производные эпотилонов, их синтез и применение
JP2002508361A5 (enExample)
JP2005511699A5 (enExample)
JP2001519410A5 (enExample)
RU98120057A (ru) Производные d-пролина
CA2431952A1 (en) Muscarinic antagonists
JP2002539181A5 (enExample)
JP2005511698A5 (enExample)
JP2003509494A5 (enExample)
JP2002520316A5 (enExample)
KR880003958A (ko) 신규 세펨화합물 및 그의 제조방법
JP2002519425A5 (enExample)
JP2003508524A5 (enExample)
JP2003503449A5 (enExample)
JP2004523478A5 (enExample)
JP2004525178A5 (enExample)